Centrose: Appoints Raymond Schinazi to executive board of members
MADISON, Wisconsin. March 30, 2010 – Centrose LLC, a biotechnology company focused on making better drugs has elected Dr. Raymond F. Schinazi to the Executive Board of Members. Dr. Schinazi is the founder of several successful biotechnology companies; including Pharmasset Inc. (VRUS), Triangle Pharmaceuticals (VIRS; acquired by Gilead), Idenix Pharmaceuticals (IDIX, 56% acquired by Novartis), and most recently RFS Pharma, LLC. Dr. Schinazi is best known for his innovative and pioneering work on several antiviral drugs many of which are now approved by the FDA, or are at various stages of clinical development. His inventions now sell more than US$2.0 billion per year and more than 94% of the HIV infected individuals take at least one of the drugs he invented.
He is currently the Francis Winship Walters Professor of Pediatrics and Chemistry and Director of the Laboratory of Biochemical Pharmacology at Emory University in Atlanta.
Professor Schinazi received his Ph.D. in Chemistry in 1976 and an Honorary D.Sc. in 2006 from Bath University, England, and completed post-doctoral training in Pharmacology at Yale University and Virology at Emory University. He has published more than 400 peer reviewed papers and seven books and has more than 80 issued US patents. Professor Schinazi has received many honors including the Georgia Biomedical Industry Growth Award, Hepatitis B Foundation Bruce Witte Annual Distinguished Award and Distinguished Scientist Award, the Russian Kalinka Award, and was named by the Ewing Marion Kauffman Foundation ‘Top Innovators in America'.
”I have known Ray for years and profoundly respect both his scientific and business insights. He is exactly what Centrose needs right now as we begin to enter a new growth phase,” commented Dr. James Prudent, President and Chief Executive Officer of Centrose.
About Centrose LLC
Centrose delivers powerful technologies for the enhancement of therapeutics and utilizes these technologies to enhance anti-cancer and anti-infective drugs. Specifically, Centrose is attaching novel sugars and targeting molecules to enhance the pharmaceutical properties of drugs with established therapeutic potential. The Company uses the proprietary CarboConnect® system to enhance, screen and fine tune drug action. Centrose obtains exclusive rights to technologies that allow it’s scientists to enhance drugs and continues to develop and patent new enhancing technologies and drug leads.
James Prudent, Ph.D.
President and CEO